Diagnostický význam sérových hladin sCD30 a sCD40L ve skupině nemocných se systémovým lupus erytematodes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F07%3A00003981" target="_blank" >RIV/61989592:15110/07:00003981 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value

Popis výsledku v původním jazyce

CD30/CD30L and CD40/CD40L are molecules from the tumor necrosis factor (TNF) superfamily. They have a major effect on communications between the B and T cells, which leads to control of maturation, proliferation, and apoptosis of those cells. The aim ofthis study was to compare the levels of a soluble form of CD30 (sCD30) and a soluble ligand CD40 (sCD40L) in patients with systemic lupus erythematosus (SLE) (n=65) and healthy controls (sCD30 n=20, sCD40L n=10) with other parameters of SLE activity. Patients were divided into subgroups according to presence or absence of lupus nephritis (LN; 33 with LN, 32 without LN). The serum levels of selected parameters were assessed also in the subgroups with low active disease characterized by European Lupus Activity Measure (ECLAM) at most 3 (n=29) and active disease with ECLAM more than 3 (n=36). The serum levels of sCD30 were 66?45,2 UI/ml in the subgroups with LN, 67,1?38,9 UI/ml in the subgroup without LN, 80,2?51,9 UI/ml in the subgroup wi

Název v anglickém jazyce

The levels of sCD30 and of sCD40L in a group of patients with systemic lupus erythematodes and their diagnostic value

Popis výsledku anglicky

CD30/CD30L and CD40/CD40L are molecules from the tumor necrosis factor (TNF) superfamily. They have a major effect on communications between the B and T cells, which leads to control of maturation, proliferation, and apoptosis of those cells. The aim ofthis study was to compare the levels of a soluble form of CD30 (sCD30) and a soluble ligand CD40 (sCD40L) in patients with systemic lupus erythematosus (SLE) (n=65) and healthy controls (sCD30 n=20, sCD40L n=10) with other parameters of SLE activity. Patients were divided into subgroups according to presence or absence of lupus nephritis (LN; 33 with LN, 32 without LN). The serum levels of selected parameters were assessed also in the subgroups with low active disease characterized by European Lupus Activity Measure (ECLAM) at most 3 (n=29) and active disease with ECLAM more than 3 (n=36). The serum levels of sCD30 were 66?45,2 UI/ml in the subgroups with LN, 67,1?38,9 UI/ml in the subgroup without LN, 80,2?51,9 UI/ml in the subgroup wi

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

<a href="/cs/project/NR8406" target="_blank" >NR8406: Prognostický význam přítomnosti hypokomplementemie pro typ a klinickou manifestaci lupusové glomerulonefritidy</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Rheumatology

ISSN

0770-3198

e-ISSN

—

Svazek periodika

26

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

BE - Belgické království

Počet stran výsledku

6

Strana od-do

723-728

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—